SciSparc Ltd. (NASDAQ:SPRC) Short Interest Down 94.9% in June

SciSparc Ltd. (NASDAQ:SPRC) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totaling 19,275 shares, a decrease of 94.9% from the May 31st total of 378,196 shares. Based on an average trading volume of 845,855 shares, the short-interest ratio is presently 0.0 days. Currently, 3.5% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of SciSparc in a report on Tuesday, May 26th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

SciSparc Stock Performance

Shares of SPRC traded down $0.42 during trading hours on Friday, hitting $5.70. 27,370 shares of the company were exchanged, compared to its average volume of 544,137. SciSparc has a fifty-two week low of $2.98 and a fifty-two week high of $80.10. The firm’s fifty day moving average is $6.99 and its 200 day moving average is $7.59.

SciSparc (NASDAQ:SPRC) last posted its quarterly earnings data on Wednesday, April 29th. The company reported ($31.60) earnings per share for the quarter. The company had revenue of $0.20 million for the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.